New hope for advanced cancer: experimental drug DB-1419 enters human trials

NCT ID NCT06554795

Recruiting now Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new experimental drug, DB-1419, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 360 participants will take part across multiple centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Show contact details

Locations

AUS01-0
RECRUITING

Randwick, New South Wales, 2031, Australia
AUS02-0
RECRUITING

Nedlands, Washington, 6009, Australia

Contact Email: •••••@•••••
AUS03-0
RECRUITING

North Ryde, New South Wales, 2109, Australia
Site CHN01-0
RECRUITING

Shanghai, Shanghai Municipality, 200030, China
Site CHN03-0
RECRUITING

Luoyang, Henan, 471000, China
Site CHN08-0
RECRUITING

Harbin, Heilongjiang, 150001, China
Site CHN09-0
NOT_YET_RECRUITING

Zhengzhou, Henan, 450000, China
Site CHN13-0
NOT_YET_RECRUITING

Jilin City, Changchun, 130000, China
Site CHN15-0
RECRUITING

Shanghai, Shanghai Municipality, 200030, China
Site CHN16-0
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Site CHN17-0
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310005, China
Site CHN18-0
RECRUITING

Chengdu, Sichuan, 610041, China
Site CHN19-0
NOT_YET_RECRUITING

Kunming, Yunnan, 650118, China
Site CHN20-0
RECRUITING

Fuzhou, Fujian, 350000, China
Site CHN21-0
RECRUITING

Changsha, Hunan, 410011, China
Site CHN23-0
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150001, China
Site CHN24-0
NOT_YET_RECRUITING

Hefei, Anhui, 230000, China
Site CHN25-0
NOT_YET_RECRUITING

Zhengzhou, Henan, 451191, China
Site CHN26-0
RECRUITING

Linyi, Shandong, 276034, China
Site CHN28-0
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100142, China
Site CHN29-0
NOT_YET_RECRUITING

Jinan, Shandong, 250117, China
Site CHN31-0
NOT_YET_RECRUITING

Shenyang, Liaoning, 110000, China
Site CHN32-0
NOT_YET_RECRUITING

Nanning, Guangxi, 530012, China
Site CHN34-0
RECRUITING

Wuhan, Hubei, 430079, China
Site CHN37-0
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310009, China
Site CHN38-0
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300000, China
Site CHN39-0
NOT_YET_RECRUITING

Hefei, Anhui, 230031, China
Site USA02-0
RECRUITING

Florida City, Florida, 32827, United States
Site USA03
RECRUITING

Huntersville, North Carolina, 28078, United States
Site USA05-0
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Site USA06-0
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Site USA07-0
RECRUITING

Nashville, Tennessee, 37203, United States
Site USA08-0
RECRUITING

Newport Beach, California, 92663, United States
Site USA09-0
RECRUITING

West Valley City, Utah, 84119, United States
Site USA11-0
RECRUITING

Chicago, Illinois, 60637, United States
Site USA12-0
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.